4.8 Article

Membrane versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Journal

CANCER RESEARCH
Volume 73, Issue 13, Pages 3938-3950

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-0002

Keywords

-

Categories

Funding

  1. NIH [R01-HL088424]
  2. Veterans Affairs Merit Award
  3. Vanderbilt University Clinical and Translational Science Award from NCRR/NIH [UL1 RR024975-01]
  4. Specialized Programs of Research Excellence in lung cancer [NCI CA 90949]
  5. Immunobiology of Blood and Vascular Systems training grant [5 T32 HL069765]

Ask authors/readers for more resources

TNF-alpha, produced by most malignant cells, orchestrates the interplay between malignant cells and myeloid cells, which have been linked to tumor growth and metastasis. Although TNF-alpha can exist as one of two isoforms, a 26-kDa membrane tethered form (mTNF-alpha) or a soluble 17-kDa cytokine (sTNF-alpha), the vast majority of published studies have only investigated the biologic effects of the soluble form. We show for the first time that membrane and soluble isoforms have diametrically opposing effects on both tumor growth and myeloid content. Mouse lung and melanoma tumor lines expressing mTNF-alpha generated small tumors devoid of monocytes versus respective control lines or lines expressing sTNF-alpha. The lack of myeloid cells was due to a direct effect of mTNF-alpha on myeloid survival via induction of cell necrosis by increasing reactive oxygen species. Human non-small cell lung carcinoma expressed varying levels of both soluble and membrane TNF-alpha, and gene expression patterns favoring mTNF-alpha were predictive of improved lung cancer survival. These data suggest that there are significant differences in the role of different TNF-alpha isoforms in tumor progression and the bioavailability of each isoform may distinctly regulate tumor progression. This insight is critical for effective intervention in cancer therapy with the available TNF-alpha inhibitors, which can block both TNF-alpha isoforms. (C) 2013 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available